Bulletin of Engineering Science and Technology (BESTEC)
Vol. 01, No. 02, 2024: 01-15

The Role of ACVR1 in the Pathogenesis of Fibrodysplasia Ossificans Progressiva

Dr. S.RAVINDRA BABU[1] M.PHARM., PHD, PROFESSOR Mallareddy institute of pharmaceutical sciences,email:ravicology@gmail.com

A R T I C L E I N F O

Keywords: Fibrodysplasia Ossificans Progressiva, Heterotopic Ossification, ACVR1 *gene, R206H mutation, BMP signaling pathway*

Received : 19, October
Revised : 28, October
Accepted: 19, November

A B S T R A C T

Fibrodysplasia Ossificans Progressiva (FOP) is a rare and severely disabling genetic disorder characterized by progressive heterotopic ossification, where bone forms in soft tissues outside the normal skeletal structure. This pathological process leads to severe immobility and a drastically reduced quality of life. The disorder is primarily caused by a recurrent activating mutation in the ACVR1 gene, which encodes a bone morphogenetic protein (BMP) type I receptor. The most common mutation, R206H, results in constitutive activation of the BMP signaling pathway, driving abnormal bone formation. This review delves into the role of ACVR1 in FOP pathogenesis, detailing the molecular mechanisms by which the R206H mutation disrupts BMP signaling and triggers heterotopic ossification. Additionally, it examines the progression of the disease, challenges in developing effective treatments, and emerging therapeutic strategies, including targeted approaches to inhibit the overactive ACVR1 receptor. These insights provide a foundation for advancing the understanding and management of FOP.

BABU

INTRODUCTION

The ACVR1 gene, located on chromosome 2q23-24, encodes the activin A receptor type I, also referred to as the bone morphogenetic protein (BMP) type I receptor. This receptor is an integral part of the BMP signaling pathway, which is vital for the regulation of bone development, homeostasis, and repair processes. The BMP pathway orchestrates a variety of cellular activities, including differentiation, proliferation, and apoptosis, particularly in the context of skeletal tissues.The activation of ACVR1 begins when BMP ligands bind to a complex of type I and type II BMP receptors at the cell surface. Specifically, BMP ligands such as BMP2, BMP4, and BMP7 bind to ACVR1, which leads to the recruitment and phosphorylation of type I receptors by the constitutively active type II receptors. Once activated, ACVR1 phosphorylates intracellular receptor-regulated SMAD proteins, primarily SMAD1, SMAD5, and SMAD8. These phosphorylated SMAD proteins then associate with SMAD4 to form a complex that translocates to the nucleus. Inside the nucleus, this complex interacts with transcriptional co-regulators to activate or repress target gene expression, including genes involved in osteoblast differentiation, bone matrix production, and bone formation. Through this tightly regulated signaling cascade, the BMP pathway ensures proper skeletal growth, bone remodeling, and repair. Dysregulation of this pathway, however, can result in pathological bone formation, as seen in fibrodysplasia ossificans progressiva (FOP).

ACVR1 Mutation in FOP

Fibrodysplasia ossificans progressiva (FOP) is primarily caused by a recurrent heterozygous mutation in the ACVR1 gene. The most prevalent mutation is a substitution of arginine with histidine at codon 206 (R206H). This mutation is located within the intracellular glycine-serine-rich (GS) domain of the receptor, a critical region responsible for modulating receptor activation.

The R206H mutation leads to a constitutive activation of the ACVR1 receptor, enabling it to signal independently of BMP ligand binding. Normally, ACVR1 activation is tightly regulated by the presence of BMP ligands, ensuring controlled downstream signaling. However, the R206H mutation disrupts this regulation, causing aberrant BMP signaling to occur even in the absence of BMP ligands. This inappropriate activation results in continuous phosphorylation of SMAD proteins, which drive the transcription of osteogenic genes.

In FOP, this hyperactive signaling promotes the pathological differentiation of mesenchymal progenitor cells, such as fibroblasts and muscle satellite cells, into osteoblasts—the cells responsible for bone formation. As a result, soft tissues, including muscles, tendons, and ligaments, are progressively transformed into bone through a process called heterotopic ossification (HO).

Mechanism of Disease Progression in FOP

The progressive nature of FOP is attributed to a self-sustaining cycle initiated by the R206H mutation:

1. Tissue Damage and Inflammation: External stimuli such as trauma, muscle strain, or viral infections can trigger localized inflammation in FOP patients. This inflammation leads to the release of pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α).
2. Activation of ACVR1 and BMP Pathway: The R206H mutation amplifies BMP signaling in response to inflammation, further activating downstream SMAD proteins and promoting osteogenic differentiation.
3. Ectopic Bone Formation: Aberrant differentiation of mesenchymal cells into osteoblasts leads to the deposition of bone in soft tissues. This heterotopic bone is often structurally normal but forms in inappropriate locations, causing stiffness, pain, and loss of mobility.

4. Self-Sustaining Cycle: The ossification process itself exacerbates inflammation, creating a feedback loop that perpetuates tissue damage, additional mesenchymal cell recruitment, and further heterotopic bone formation.

This cycle explains why FOP progresses over time, with episodes of heterotopic ossification often triggered by seemingly minor traumas or inflammatory events. The cumulative effect of these ossification events leads to significant morbidity, as affected individuals gradually lose mobility and experience profound reductions in quality of life.

Significance of Understanding ACVR1 Mutation

The discovery of the R206H mutation in ACVR1 has significantly advanced the understanding of FOP pathogenesis. It has not only elucidated the molecular underpinnings of the disease but also identified ACVR1 as a key therapeutic target. By focusing on strategies to inhibit the overactive ACVR1 receptor or modulate downstream BMP signaling, researchers aim to develop treatments that can halt or reverse the pathological processes of heterotopic ossification in FOP patients.

Literature Review

Investigations into the Role of ACVR1 in FOP Pathogenesis.Numerous studies have examined the role of ACVR1 in the development and progression of fibrodysplasia ossificans progressiva (FOP), consistently demonstrating its central role in the disease. One notable study of Italian FOP patients found that all cases were associated with the ACVR1 R206H mutation, further confirming the mutation's significance in FOP pathogenesis. Another investigation into the signaling activity of various FOP-associated ACVR1 mutations revealed that these mutations result in altered protein folding and interactions, leading to an activated receptor state. These findings underscore the molecular mechanisms driving the aberrant bone formation characteristic of FOP.

A comprehensive literature search was conducted across the PubMed, Embase, and Web of Science databases to identify studies focusing on the role of ACVR1 in FOP. Search terms included "Fibrodysplasia Ossificans Progressiva," "ACVR1," "Activin A receptor type I," "BMP signaling," and "heterotopic ossification." The search was restricted to English-language articles and prioritized studies examining:

- The genetic basis of FOP.
- Functional consequences of ACVR1 mutations.
- Therapeutic strategies targeting ACVR1.

A variety of sources, including original research, review articles, case reports, and preclinical studies, were included in the review to provide a comprehensive understanding of the topic. Key findings from pivotal studies are summarized below.

Key Findings from the Literature

1. Identification of the ACVR1 R206H Mutation

The landmark discovery by Shore et al. identified the heterozygous ACVR1 R206H mutation as the causative genetic defect in FOP. This mutation remains the most common and well-characterized genetic alteration associated with the disease. Its identification established a crucial link between ACVR1 mutations and the development of heterotopic ossification, laying the foundation for subsequent research into the molecular underpinnings of FOP.

2. Functional Characterization of the ACVR1 R206H Mutation

Extensive research has demonstrated that the R206H mutation results in constitutive activation of the ACVR1 receptor, even in the absence of BMP ligands. This leads to enhanced BMP signaling and promotes the aberrant differentiation of mesenchymal progenitor cells into osteoblasts, driving the formation of heterotopic bone in soft tissues. These studies highlight the mutation's role in disrupting the normal regulation of bone morphogenetic protein signaling, a key process in skeletal homeostasis.

3. Preclinical Studies Targeting ACVR1

Several preclinical studies have explored therapeutic strategies targeting ACVR1, including:

- Small molecule inhibitors: Designed to inhibit the overactive ACVR1 receptor, these molecules have shown promise in reducing heterotopic ossification in animal models of FOP.
- Gene therapy approaches: Preclinical research has investigated methods to correct the ACVR1 R206H mutation or silence its expression, with promising results in mitigating disease progression in experimental models.

These studies provide a strong rationale for the development of targeted therapies aimed at modulating ACVR1 activity.

Enhancing the Methodology

To further strengthen this section, specific citations for the studies mentioned should be included, providing detailed references to the original research. Additionally, reporting the number of articles retrieved during the literature search and the criteria for their inclusion in the review would improve the rigor and transparency of the methodology. By adding these details, the summary would better reflect the breadth and depth of evidence supporting the central role of ACVR1 in FOP pathogenesis.

Methodology

This section should describe the methodology used for the literature review. Here's a suggested structure and content:

- **Search Strategy:** Detail the databases used (e.g., PubMed, Embase, Web of Science), the keywords used (e.g., "Fibrodysplasia Ossificans Progressiva," "ACVR1," "R206H mutation," "heterotopic ossification," "BMP signaling"), and any date restrictions or other filters applied. Be specific about the search strings used, including Boolean operators. For example, a search string could be ("Fibrodysplasia Ossificans Progressiva" AND "ACVR1" AND "R206H") OR ("heterotopic ossification" AND "ACVR1").
- **Inclusion/Exclusion Criteria:** Clearly define the criteria used to select relevant articles. This might include criteria based on study design (e.g., clinical trials, preclinical studies, review articles), language (e.g., English only), publication date, or specific topics of interest (e.g., genetic studies, functional studies, therapeutic studies).
- **Study Selection Process:** Describe the process used to screen and select articles. This might involve a multi-step process, such as initial screening based on titles and abstracts, followed by full-text review of potentially relevant articles. Mention the number of articles identified at each stage of the process. A flow diagram can be helpful to visualize the study selection process.
- **Data Extraction:** Explain how data was extracted from the selected articles. This might involve creating a standardized data extraction form to collect information on study design, sample size, key findings, and other relevant variables.
- **Quality Assessment (if applicable):** If a quality assessment of included studies was performed, describe the method used and the criteria applied. This is particularly relevant for systematic reviews.

By providing a detailed and transparent methodology section, you enhance the reproducibility and credibility of your literature review.

RESEARCH RESULTS

Basal BMP-pSMAD1/5/8 signaling activity by FOP ACVR1 variants is elevated

The most prevalent FOP ACVR1 mutation, referred to as the FOP 'classic' mutation, is R206H (c.617G>A) and is located within the GS domain (Figure 1) named for the abundance of glycine and serine residues. In the absence of ligand-receptor interaction through the extra-cellular ligand-binding domain (LBD)



Figure 1. Schematic of human ACVR1 protein with functional domains

In the absence of exogenous ligands, C2C12 cells (a myoblast cell line) transfected with V5-tagged constructs containing the FOP ACVR1 receptor GS domain mutation R206H showed elevated phosphorylated Smad1/5/8 (pSmad1/5/8) levels by immunoblotting, indicating increased receptor activity under basal conditions. As expected, the CA Q207D mutation showed much higher levels of activation than the FOP ACVR1 mutations.Among the PK domain ACVR1 FOP mutations, only the variant G356D KD mutant receptor showed significantly increased activation under unstimulated conditions .



GS domain and PK variant mutations show different dose-response sensitivity to BMP4

To investigate whether ACVR1 FOP mutant receptors show varied sensitivity and signaling response to levels of ligands, transfected iMEFs were treated with increasing concentrations of BMP4 followed by a Smad1 phosphorylation assay (Figure 3). The sensitivity of this assay is much greater than the luciferase reporter assay, as it directly measures phosphorylation of the receptor substrate Smad1 rather than quantifying a transcriptional target reporter, and therefore indirectly assays the receptor kinase activity



Figure 3. BMP4 dose response by FOP mutants.

This section should present the key findings from the literature search in a clear and organized manner. Since you've already outlined the key findings in the Literature Review section, you can expand on those points here. Organize the results thematically, focusing on the following aspects:

- **Prevalence and Demographics:** Report the estimated prevalence of FOP and any demographic trends observed in the literature. Mention any geographical, ethnic, racial, or gender predispositions if reported (Gregson et al., 2010)(Petrie et al., 2009).
- **Genetic Basis of FOP:** Describe the *ACVR1* R206H mutation in detail, including its location and functional consequences. Mention other less common mutations if any are reported in the literature (A Case of Fibrodysplasia Ossificans Progressiva in a 5-year-old Boy with all Musculoskeletal Features and Review of the Literature, 2019). You can also discuss the inheritance pattern of FOP and the likelihood of spontaneous mutations (Bocciardi et al., 2008)(Gregson et al., 2010).
- **Molecular Mechanisms of *ACVR1* in FOP:** Explain how the R206H mutation affects the BMP signaling pathway, leading to heterotopic ossification. Discuss the role of downstream signaling molecules and target genes. Include details about the constitutive activation of the receptor (Variable signaling activity by FOP ACVR1 mutations, 2018).
- **Clinical Manifestations of FOP:** Describe the typical clinical features of FOP, including the progression of heterotopic ossification, the involvement of specific muscle groups, and the associated complications. Mention the great toe abnormalities and other skeletal features often observed in FOP patients (Petrie et al., 2009). Discuss the prognosis and typical life expectancy of individuals with FOP (Fibrodysplasia Ossificans Progressiva: Practice Essentials, Pathophysiology, Epidemiology, 2022).

- **Therapeutic Strategies:** Summarize the current and emerging therapeutic approaches for FOP, focusing on those targeting *ACVR1*. Discuss the rationale behind these approaches, the preclinical and clinical evidence supporting their use, and the challenges in developing effective treatments.

Remember to cite the relevant sources for each finding. For example, when discussing the poor prognosis of FOP, you can cite (Fibrodysplasia Ossificans Progressiva: Practice Essentials, Pathophysiology, Epidemiology, 2022). When mentioning the prevalence of FOP, you can cite (Gregson et al., 2010)(Petrie et al., 2009). Adding more relevant articles to your library will allow me to provide more specific citations and enrich the results section.

Discussion

This section should interpret the results and discuss their implications in the context of existing knowledge. Consider the following points:

- **Significance of *ACVR1* in FOP Pathogenesis:** Reiterate the central role of *ACVR1* in FOP and discuss how the R206H mutation contributes to the disease process.
- **Challenges in FOP Treatment:** Discuss the challenges in developing effective treatments for FOP, such as the difficulty in targeting the *ACVR1* pathway without disrupting normal bone development.
- **Future Research Directions:** Highlight promising areas of future research, such as the development of more specific *ACVR1* inhibitors, gene therapy approaches, and strategies to prevent flare-ups of heterotopic ossification. Mention the importance of understanding the role of other genes and pathways that may contribute to FOP.
- **Limitations of the Review:** Acknowledge any limitations of the literature review, such as the potential for publication bias or the inclusion of studies with varying levels of methodological quality.

Conclusion

This section should provide a concise summary of the main findings and their implications. Restate the central role of *ACVR1* in FOP pathogenesis and

emphasize the need for continued research to develop effective therapies for this debilitating disorder. You can also briefly mention the potential impact of future research on improving the lives of individuals with FOP.The Conclusion section should succinctly summarize the key findings of your review, emphasizing the significance of *ACVR1* in the pathogenesis of Fibrodysplasia Ossificans Progressiva. It should also highlight the need for continued research to develop effective therapies and improve the lives of individuals affected by this debilitating disorder. Here's a more detailed guide:

1. **Recap of Key Findings:** Briefly reiterate the central role of the *ACVR1* gene, specifically the R206H mutation, in the development of FOP. Summarize the impact of this mutation on BMP signaling, leading to the characteristic heterotopic ossification observed in FOP patients. Mention the clinical manifestations of the disease, highlighting its progressive nature and the resulting functional limitations. If you discussed specific therapeutic strategies in the Results section, briefly mention the most promising avenues.
2. **Emphasis on the Need for Research:** Underscore the current limitations in treating FOP and emphasize the critical need for continued research. Highlight the importance of exploring new therapeutic targets, such as more selective *ACVR1* inhibitors or alternative pathways involved in heterotopic ossification. Mention the potential of emerging therapeutic modalities like gene therapy or RNA interference.
3. **Potential Impact of Future Research:** Briefly discuss the potential impact of future research on improving the lives of individuals with FOP. This could include improved quality of life, increased mobility and independence, and extended lifespan. Focus on the translational potential of research findings and their ability to lead to the development of effective clinical interventions.
4. **Concluding Statement:** End with a strong concluding statement that reinforces the importance of continued research efforts to address the unmet medical needs of individuals with FOP. This statement should

convey a sense of hope and optimism for future advancements in the field.

Here's an example of a concluding paragraph:

"In conclusion, this review underscores the crucial role of *ACVR1* in the pathogenesis of FOP, highlighting the devastating consequences of the R206H mutation on BMP signaling and skeletal development. While significant progress has been made in understanding the molecular mechanisms underlying FOP, effective treatment options remain limited. Continued research focusing on targeted therapies, such as selective *ACVR1* inhibitors and gene therapy approaches, holds immense promise for improving the lives of individuals with FOP. Further investigation into the complex interplay of genetic and environmental factors contributing to disease progression is essential for developing comprehensive management strategies and ultimately achieving a cure for this debilitating disorder."

References

Bocciardi, R., Bordo, D., Duca, M D., Rocco, M D., & Ravazzolo, R. (2008, October 1). Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Springer Nature, 17(3), 311-318. https://doi.org/10.1038/ejhg.2008.178

Fibrodysplasia Ossificans Progressiva: Practice Essentials, Pathophysiology, Epidemiology. (2022, May 13)

Gregson, C L., Hollingworth, P., Williams, B., Petrie, K A., Bullock, A N., Brown, M A., Tobias, J H., & Triffitt, J T. (2010, October 30). A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Elsevier BV, 48(3), 654-658. https://doi.org/10.1016/j.bone.2010.10.164

Petrie, K A., Lee, W., Bullock, A N., Pointon, J J., Smith, R., Russell, R., Brown, M A., Wordsworth, B P., & Triffitt, J T. (2009, March 30). Novel Mutations in ACVR1 Result in Atypical Features in Two Fibrodysplasia Ossificans Progressiva Patients. Public Library of Science, 4(3), e5005-e5005. https://doi.org/10.1371/journal.pone.0005005

Shore, J H M X E M. (2018, April 26). Variable signaling activity by FOP ACVR1 mutations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866189/

Toksoy, M C B K O U. (2019, February 12). A Case of Fibrodysplasia Ossificans Progressiva in a 5-year-old Boy with all Musculoskeletal Features and Review of the Literature. https://pubmed.ncbi.nlm.nih.gov/30740372

Makutam, Viswakanth & Achanti, Sai & Doostan, Marjan. (2024). INTEGRATION OF ARTIFICIAL INTELLIGENCE IN ADAPTIVE TRIAL DESIGNS: ENHANCING EFFICIENCY AND PATIENT-CENTRIC OUTCOMES. International Journal of Advanced Research. 12. 205-215. 10.21474/IJAR01/19245.

Varagani, Srinivasarao & Safwan, Mohammad & Makutam, Viswakanth & Moparthi, Swapna & Vaishnavi, Sri & Kondru, Sowjanya & Yadav, Ritu & Dhiraj, Kohale. (2024). A comparative study on assessment of safety and efficacy of Diclofenac, Naproxen and Etoricoxib in reducing pain in osteoarthritis patients -An observational study. 10. 31-38. 10.22192/ijcrms.2024.10.08.003.

Priya, Maroju & Makutam, Viswakanth & Mohmed, Shaikh & Javid, Adnan & Safwan, Mohammad & Ahamad, Tanwir & Sathya, Alapati & Guptha, Sai & Dhiraj, Kohale & Mathew, Anannya & Varagani, Srinivasarao. (2024). AN OVERVIEW ON CLINICAL DATA MANAGEMENT AND ROLE OF PHARM.D IN CLINICAL DATA MANAGEMENT. World Journal of Advanced Pharmaceutical and Medical Research. 10. 299.

Makutam, Viswakanth & Sundar, D & Vijay, M & Saipriya, T & Rama, B & Rashmi, A & Rajkamal, Bigala & Parameshwar, P. (2020). PHARMACOEPIDEMOLOGICAL AND PHARMACOECONOMICAL STUDY OF ANALGESICS IN TERTIARY CARE HOSPITAL:

RATIONAL USE. World Journal of Pharmaceutical Research. 9. 787-803. 10.20959/wjpr20209-18206.

Makutam, Viswakanth. (2018). REVIEW ARTICLE ON FIBRODYSPLASIA OSSIFICANS PROGRESSIVA. 7. 359. 10.20959/wjpps20186-11696.